HCW Biologics regains full Nasdaq Capital Market compliance; Panel Monitor through June 2026

HCW Biologics Inc.

On June 24, 2025, Nasdaq confirmed compliance with minimum stockholders' equity (Rule 5550(b)(1)).
Had previously regained compliance with bid price, public float, and market value rules on May 13, 2025.
All listing criteria now met; previously disclosed compliance matters closed.
Subject to Panel Monitor for one year through June 23, 2026; failure requires hearing not plan submission.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.